ACM
DMRA

Asymmetry Capital Management’s Damora Therapeutics DMRA Stock Holding History

Asymmetry Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,439
Closed -$308K – 38
2021
Q2 		$308K Sell
2,439
-2,102
-46% -$286K 0.21% 30
2021
Q1 		$690K Sell
4,541
-8,953
-66% -$2.44M 0.36% 29
2020
Q4 		$4.22M Buy
+13,494
New +$5.02M 1.92% 22

Other funds holding DMRA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Asymmetry Capital Management's DMRA Position: Q3 2021 in Review

Asymmetry Capital Management sold out of Damora Therapeutics (DMRA) in Q3 2021, closing a stake of 2,439 shares — an estimated $308K sold.

Asymmetry Capital Management first reported a position in DMRA in Q4 2020 and held it in 3 quarters. The position peaked at $4.22M in Q4 2020. 25 funds tracked by Wall St. Rank hold DMRA as of Q3 2021.

  • Asymmetry Capital Management reported no remaining Damora Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 2,439 Damora Therapeutics shares in Q3 2021, an estimated $308K.
  • Asymmetry Capital Management first reported a position in Damora Therapeutics in Q4 2020 and held it in 3 quarters.
  • Asymmetry Capital Management's Damora Therapeutics position peaked at $4.22M in Q4 2020.
  • 25 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2021.

Based on Asymmetry Capital Management's 13F filing for Q3 2021, filed 4 Nov 2021.